Clinical applications of growth factors in bone injuries: experience with BMPs.
The management of open fractures and delayed or non unions continue to be complicated by high rates of treatment failure and significant patient disability and dissatisfaction. The use of bone morphogenetic proteins (BMPs) in the treatment of these injuries has been assessed by several authors. BMPs induce the process of bone healing by recruiting bone-forming cells to the area of lesion. The use of BMP currently has two FDA-approved indications: treatment of open tibial fractures treated with intramedullary fixation and treatment of tibia long bone non-union. Despite this limited target, off-label BMP use continues to push the spectrum for new applications. This review describes the current evidence for the use of BMPs in open fractures and non-unions.
Department of Biotechnology and Life Sciences (DBSV), University of Insubria, Varese, Italy. mario.ronga@uninsubria.it
Mario
M
Ronga
Alessandro
A
Fagetti
Gianluca
G
Canton
Elia
E
Paiusco
Michele Francesco
MF
Surace
Paolo
P
Cherubino
D055396:Bone Morphogenetic Protein 2 / Q000627:therapeutic use*; D055419:Bone Morphogenetic Protein 7 / Q000627:therapeutic use*; D001861:Bone Regeneration; D003362:Cost-Benefit Analysis; D005260:Female; D005593:Fracture Fixation, Internal / Q000379:methods; D017102:Fracture Healing; D005597:Fractures, Open / Q000473:pathology / Q000628:therapy*; D005599:Fractures, Ununited / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D016032:Randomized Controlled Trials as Topic; D013978:Tibial Fractures / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome
D055396:Bone Morphogenetic Protein 2; D055419:Bone Morphogenetic Protein 7